Detalles de la búsqueda
1.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34758069
2.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
3.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
4.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28032641
5.
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Anticancer Drugs
; 28(7): 717-722, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28582279
6.
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Lancet Oncol
; 17(1): 57-66, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26655425
7.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27575024
8.
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
Haematologica
; 100(11): 1451-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26315931
9.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25088940
10.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet
; 381(9873): 1203-10, 2013 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23433739
11.
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.
Haematologica
; 99(6): 1095-100, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24584349
12.
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
Am J Hematol
; 89(12): E239-43, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25196783
13.
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.
J Clin Oncol
; 41(25): 4143-4153, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37352476
14.
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.
BMC Cancer
; 12: 165, 2012 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22559145
15.
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
Blood
; 114(16): 3382-91, 2009 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19605849
16.
Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany.
Onkologie
; 33(1-2): 39-44, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20164660
17.
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials.
Clin Cancer Res
; 26(24): 6559-6567, 2020 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32943459
18.
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.
J Clin Oncol
; 33(18): 2028-34, 2015 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25987694
19.
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
J Clin Oncol
; 33(32): 3718-26, 2015 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26261259
20.
Costs of treatment of colorectal cancer in different settings in Germany.
Eur J Health Econ
; 5(3): 270-3, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15714348